Related Experiment Video
Updated: Jun 16, 2026
09:18
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
PET and PET/CT for pancreatic malignancies
Dominique Delbeke1, William H Martin
1Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, 21st Avenue South and Garland, Nashville, TN 37232-2675, USA. Dominique.delbeke@vanderbilt.edu <Dominique.delbeke@vanderbilt.edu>
Surgical Oncology Clinics of North America
|February 18, 2010
Summary
Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging aids in diagnosing pancreatic cancer when CT scans are unclear. FDG PET also detects metastatic disease, preventing unnecessary surgeries and monitoring treatment effectiveness.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Computed tomography (CT) may fail to detect small pancreatic tumors or metastatic disease.
- Fine-needle aspiration (FNA) biopsies can be inconclusive in diagnosing pancreatic cancer.
- Accurate staging is crucial for treatment planning and avoiding noncurative resections.
Purpose of the Study:
- To evaluate the utility of FDG PET imaging in the diagnosis and staging of pancreatic carcinoma.
- To assess the role of FDG PET in detecting metastatic disease and monitoring treatment response.
- To determine the effectiveness of integrated PET/CT imaging for pancreatic cancer management.
Main Methods:
- Review of FDG PET imaging studies in patients with suspected pancreatic cancer.
- Comparison of FDG PET findings with CT, FNA, and histopathological results.
- Analysis of FDG PET's ability to detect occult metastases and differentiate post-therapy changes.
Main Results:
- FDG PET is valuable for preoperative diagnosis when CT is indeterminate or FNA is nondiagnostic.
- FDG PET effectively identifies CT-occult metastatic disease, aiding in M staging and restaging.
- The technique shows promise in monitoring neoadjuvant chemoradiation and differentiating recurrence from post-therapy changes.
- FDG PET utility is limited in periampullary carcinoma but helpful for M staging.
Conclusions:
- FDG PET imaging is a valuable tool for diagnosing and staging pancreatic cancer, especially in challenging cases.
- Integrated PET/CT imaging offers optimal visualization and interpretation for improved patient care.
- FDG PET assists in treatment monitoring and preventing noncurative surgeries by detecting metastatic disease.
